TCGA data indicated that the patients with high PLK1 expression in lung adenocarcinoma, renal clear cell carcinoma, and bladder cancer exhibit shorter overall survival, whereas the patients with high PLK1 expression in squamous cell carcinoma, rectal cancer, and thymoma exhibit a better prognosis [35]. This evidence concerns the gene PLK1 and urinary bladder cancer.